 - Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 CTLA-4 antibody including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways. 